August 19th 2020
By Tony Hagen
Monoclonal antibodies may play a frontline role in dealing with COVID-19 infections, according to Anthony S. Fauci, MD.
By Skylar Jeremias
US administrative and legislative efforts are moving the United States and Germany more into alignment on drug cost management philosophy, according to a review.
August 17th 2020
A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .
Pharmacists in Ireland say the country is losing out on hundreds of millions of dollars in savings owing to the absence of a biosimilar substitution policy.
August 15th 2020
There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.
August 14th 2020
Up-and-coming Henlius Biotech consolidates its footing in the biosimilar world with another regulatory approval.
By Deana Ferreri, PhD
Celltrion finds fault with a critique of equivalence margins used to approve its infliximab biosimilar.
August 13th 2020
Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.
August 12th 2020
Opening the door to biosimilar competition starts with breaking down the patent barrier, says Christine Simmon, JD.
August 11th 2020
United States Pharmacopeia (USP), the FDA, and others deliver constructive critique on how India can bolster quality in its biopharmaceutical industry.
